Earnings summaries and quarterly performance for Hinge Health.
Executive leadership at Hinge Health.
Board of directors at Hinge Health.
Research analysts who have asked questions during Hinge Health earnings calls.
Bradley Sills
Bank of America
1 question for HNGE
Also covers: ADBE, BILL, CRM +14 more
Brian Peterson
Raymond James Financial
1 question for HNGE
Also covers: BIGC, BLKB, BOX +18 more
Craig Hettenbach
Morgan Stanley
1 question for HNGE
Also covers: ACCD, AMWL, ARDT +10 more
Elizabeth Anderson
Evercore ISI
1 question for HNGE
Also covers: AGL, ALGN, CAH +23 more
Jailendra Singh
Truist Securities
1 question for HNGE
Also covers: ACCD, AGL, AMWL +16 more
Richard Close
Canaccord Genuity Group
1 question for HNGE
Also covers: ACCD, AHCO, CLOV +15 more
Ryan Daniels
William Blair & Company, L.L.C.
1 question for HNGE
Also covers: ACCD, AGL, ALHC +12 more
Saket Kalia
Barclays Capital
1 question for HNGE
Also covers: ADBE, ADSK, ALRM +24 more
Recent press releases and 8-K filings for HNGE.
Hinge Health Announces Share Repurchase Program
HNGE
Share Buyback
- Hinge Health, Inc. announced a $250 million share repurchase program, authorized by its board of directors on November 10, 2025.
- The company intends to fund these repurchases with existing cash and cash equivalents and ongoing cash from operations.
- As of the end of Q3 2025, Hinge Health had nearly $500 million in cash and investments and generated $108 million in cash from operations and $118 million in free cash flow during the first three quarters of 2025.
Nov 12, 2025, 2:05 PM
Hinge Health Reports Strong Q3 2025 Results and Raises Full-Year Guidance
HNGE
Earnings
Guidance Update
New Projects/Investments
- Hinge Health reported strong Q3 2025 financial results, with revenue reaching $154 million, representing 53% year-over-year growth, and gross margin improving to 83% from 79% in Q3 last year.
- The company achieved a 20% operating margin and generated $81 million in free cash flow, resulting in a 53% free cash flow margin for Q3 2025.
- Hinge Health raised its full-year 2025 guidance, now expecting revenue between $572-$574 million and non-GAAP income from operations between $106-$108 million, citing strong business fundamentals and operational efficiency gains from AI initiatives.
- Operational highlights include surpassing 1.5 million lifetime members and significant advancements in AI, such as the new Robin AI care assistant and TruMotion computer vision technology for movement analysis. AI initiatives also led to a 120% increase in code output and new features pushed three times faster in Q3 2025 compared to Q3 2024.
- A lockup for 77 million shares is scheduled to expire on November 17th, 2025, with shares becoming free to trade on November 18th, 2025.
Nov 4, 2025, 9:30 PM
Hinge Health Announces Strong Q3 2025 Results and Updates 2025 Guidance
HNGE
Earnings
Guidance Update
Product Launch
- Hinge Health (HNGE) reported Q3 2025 revenue of $154 million, a 53% year-over-year increase, alongside a non-GAAP gross margin of 83% and non-GAAP income from operations of $30 million, representing a 20% operating margin.
- The company's client count grew by 25% year-over-year to 2,560, and LTM calculated billings reached $624 million, a 50% year-over-year increase.
- For Q4 2025, Hinge Health expects revenue between $155 million and $157 million. The updated full-year 2025 revenue guidance is $572 million to $574 million, reflecting 47% year-over-year growth.
- Key product developments include the introduction of Robin AI, a member-facing AI care assistant, and Movement Analysis, which uses AI-motion tracking technology.
Nov 4, 2025, 9:30 PM
Quarterly earnings call transcripts for Hinge Health.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more
Let Fintool AI Agent track Hinge Health's earnings for you
Get instant analysis when filings drop